ISO TREATMENT Sample Clauses

ISO TREATMENT. It is intended that the Option shall qualify as an "incentive stock option" as described in Section 422 of the Internal Revenue Code of 1986, as amended.
AutoNDA by SimpleDocs
ISO TREATMENT. It is not intended that the Option shall qualify as an "incentive stock option" as described in section 422 of the Internal Revenue Code of 1986, as amended.
ISO TREATMENT. It is intended that the Option shall qualify as an “incentive share option” as described in Section 422 of the Internal Revenue Code of 1986, as amended within the limitations outlined in Section 2.5 of the 2000 Plan.
ISO TREATMENT. The Options are intended to satisfy the requirements of Section 422 of the Code relating to the issuance of “incentive stock options” (“ISOs”). In addition to the other terms and conditions relating to the Options as described elsewhere in this Agreement, the following applies with respect the Options: (i) the Administrator has determined that as of the date hereof, the fair market value of one share of Common Stock of the Company does not exceed the Exercise Price; (ii) Optionee shall not be granted Options under this Agreement during any twelve-month period covering more than 1,000,000 shares; and (iii) this Agreement, and the issuance of the Options hereunder, has been approved by the holders of a majority of the Company’s outstanding shares of stock.
ISO TREATMENT. If designated in the Notice of Grant as Incentive Stock Options, the Options granted pursuant to this Award are intended to qualify for favorable tax treatment as Incentive Stock Options (also known as “ISOs”) as defined in Section 422 of the Internal Revenue Code. Nevertheless, to the extent that the Fair Market Value of shares of Common Stock with respect to which ISOs are exercisable for the first time during any calendar year exceeds $100,000, this Option shall be treated as a Nonstatutory Stock Option. Furthermore, neither the Company nor any other person or entity guarantees, warrants or otherwise represents that this Award will produce any favorable or desired tax or other result. If Optionholder sells or otherwise disposes of any of the shares of Common Stock acquired pursuant to an ISO on or before the later of (1) the date two (2) years after the Date of Grant as set forth in Section I, and (2) the date one (1) year after the date of exercise, Optionholder must immediately notify the Company in writing of such disposition.
ISO TREATMENT. The Option is intended to qualify as an Incentive Stock Option pursuant to Section 422 of the Internal Revenue Code of 1986, as amended. Provided, however, that if the aggregate fair market value (determined on the Date of Grant) of the Incentive Stock Options (under this and any other plan of the Company and its Subsidiaries or parent) which become exercisable by you for the first time during any calendar year exceeds $100,000, such Options shall be treated as Non-statutory Stock Options.
ISO TREATMENT. The Options shall, to the fullest extent permitted under applicable tax laws, be structured to qualify as "incentive stock options" with the meaning of Section 422(b) of the Internal Revenue Code.
AutoNDA by SimpleDocs

Related to ISO TREATMENT

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • National Treatment In the sectors inscribed in its Schedule, and subject to any conditions and qualifications set out therein, each Party shall accord to services and service suppliers of the other Party treatment no less favourable than that it accords, in like circumstances, to its own services and service suppliers.

  • Equal Treatment No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered and paid to all the Subscribers and their permitted successors and assigns.

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State. (2) In addition, each Contracting Party shall accord to investors of the other Contracting Party, including in respect of returns on their investments, treatment which shall not be less favourable than that accorded to investors of any third State. (3) The provisions of paragraphs (1) and (2) above shall not be construed so as to oblige one Contracting Party to extend to the investors of the other the benefit of any treatment, preference or privilege resulting from: (a) Any existing or future free trade area, customs unions, monetary union or similar international agreement or other forms of regional cooperation to which one of the Contracting Parties is or may become a party, or (b) Any matter pertaining wholly or mainly to taxation.

  • Denial of Preferential Tariff Treatment The Customs Authority of the importing Party may deny a claim for preferential tariff treatment when: (a) the good does not qualify as an originating good; or (b) the importer, exporter or producer fails to comply with any of the relevant requirements of this Chapter.

  • Confidential Treatment The parties hereto understand that any information or recommendation supplied by the Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Investment Manager, the Company or such persons the Investment Manager may designate in connection with the Fund. The parties also understand that any information supplied to the Sub-Adviser in connection with the performance of its obligations hereunder, particularly, but not limited to, any list of securities which may not be bought or sold for the Fund, is to be regarded as confidential and for use only by the Sub-Adviser in connection with its obligation to provide investment advice and other services to the Fund.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!